The Pandemic Fund
Meeting the 2030 Target on Reducing the Global Burden of AMR: Pathways for Strengthening and Leveraging Surveillance in Developing Countries
By Prateek Sharma and Viviana Munoz Tellez
Antimicrobial Resistance (AMR) poses a major and growing threat to global health, yet low- and middle-income countries (LMICs) face significant challenges in implementing AMR surveillance –collection and analysis of data on AMR. Global AMR targets, including the United Nations’ goal of reducing AMR-associated deaths by 10 percent by 2030 and achieving diagnostic capacity in 80 percent of countries, rely on surveillance data that are often incomplete, hospital-centered, and unrepresentative of community infections in LMICs. While the Global Antimicrobial Resistance and Use Surveillance System (GLASS) of the World Health Organization (WHO) provides a standardized framework, in LMICs limited access to diagnostics, high laboratory costs, and reliance on data from specialized hospitals constrain participation and data comparability. Modeling studies have helped quantify the global burden of AMR, yet their reliance on sparse LMIC data underscores the need for improved primary surveillance. Achieving the United Nations’ 2030 target—where 80 per cent of countries can test resistance in all GLASS pathogens—will require substantial investment, technical support, and sustained political commitment. Embedding AMR surveillance within health systems and strengthening pandemic prevention and preparedness can help unlock external funding for eligible LMICs through the Pandemic Fund and the Global Fund.
(more…)
Assessing the State of Play in the WHO Pandemic Instrument Negotiations
By Viviana Muñoz Tellez
This Policy Brief discusses the state of play of the negotiations of the pandemic instrument at the World Health Organization. The Intergovernmental Negotiating Body (INB) is increasing its meetings as the target deadline for completion in the first half of 2024 draws closer. To advance, the political will needs to be scaled up in the next months. The expectations should not be lowered to focus on the lowest common denominator. Real progress needs to be made in priority areas of concern for developing countries to keep momentum.
(more…)
Where Does Global Health Funding Come From and Where Does It Go?
By Germán Velásquez
In theory, the World Health Organization (WHO) is the coordinating agency for global health. Influential private and public actors have claimed the relevance and central role of this United Nations (UN) agency. In practice, paradoxically, the money budgeted for health goes largely to other institutions and not to the WHO. New institutions and mechanisms have been created to which funds are channeled (GAVI, The Global Fund, Act-A, CEPI, COVAX, etc.). These institutions or mechanisms are, in most cases, public-private partnerships where the pharmaceutical industry is usually present. Official Development Assistance is important but represents only 1 per cent of what developing countries’ expenditure on health. How much is spent to promote global health and where this money goes is the subject of this paper. After the experience with COVID-19, a fundamental question that must be addressed is how the global public interest can be preserved by creating common public goods and protecting human rights in the prevention, preparedness, and response to present and future pandemics.
(more…)
De dónde viene y a dónde va el financiamiento para la salud mundial
Por Germán Velásquez
En teoría la OMS es la agencia coordinadora de la salud mundial, y los grandes actores, privados y públicos, revindican la relevancia y el rol central de esta agencia de Naciones Unidas. En la práctica, paradójicamente, los dineros para la salud van en gran parte a otras instituciones y no a la OMS o incluso se crean nuevas instituciones o mecanismos donde se canalizan los nuevos fondos (GAVI, Fondo Mundial, Act-A, CEPI, COVAX etc.) Estas instituciones o mecanismos son, en la mayoría de los casos, partenariados público-privados donde está presente la industria farmacéutica. La Ayuda Oficial para el Desarrollo es importante pero sólo representa el 1% de lo que invierten los países en desarrollo en salud. En qué se gasta para promover la salud global y a dónde va este dinero es el objeto de este documento. Una de las preguntas que debemos hacernos tras la experiencia con COVID-19 es cómo vamos a preservar el interés público global mediante la creación de bienes públicos comunes y la protección de los derechos humanos en las actividades de prevención, preparación y respuesta a las pandemias presentes y futuras.
(more…)
